Robert Šeparović
University Hospital Centre Zagreb · 205 works · 885 citations · h-index 10
Top works
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
- Rapid hair depigmentation in patient treated with pazopanib
- Expression of Cancer/Testis Tumor Associated Antigens in Cervical Squamous Cell Carcinoma
- Immunohistochemical Analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR Antigen Expression in Medullary Breast Cancer
- Fecal Microbiota Transplantation in Refractory Immune-Mediated Colitis: Case Series and Review of the Literature
- Uncommon Side Effects of Sunitinib Therapy in a Patient with Metastatic Renal Cell Cancer: Case Report
- Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial
- Unusual features of metastatic atypical carcinoid of the larynx
- Parachordoma: A Case Report
- PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial
- Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: a retrospective immunohistochemical study
- Isolated splenic metastasis from colorectal carcinoma in a high risk patient: a case report.
- Prognostic value of prominent DCIS component in the breast-conserving therapy of stage I and II invasive ductal breast cancer
- Real-World Efficacy and Safety of Bevacizumab in the First-Line Treatment of Metastatic Cervical Cancer: A Cohort Study in the Total Population of Croatian Patients
- Difference in Estimation of Side Effects of Chemotherapy between Physicians and Patients with Early-Stage Breast Cancer: The Use of Patient Reported Outcomes (PROs) in the Evaluation of Toxicity in Everyday Clinical Practice
- Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer
- Trastuzumab plus capecitabine with or without pertuzumab in patients with HER2-positive MBC whose disease has progressed during or following trastuzumab-based therapy for first-line metastatic disease: A multicenter, randomized, two-arm, phase II study (PHEREXA).
- Globalization of clinical research in oncology: Status, challenges, and future directions
- Association of Breast Cancer Symptoms with Patients' Quality of Life and Depression; A Croatian Cross-Sectional Study.
- Abstract PD3-03: Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial